Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

ADER, Florence, Nathan PEIFFER-SMADJA, Julien POISSY, Maude BOUSCAMBERT-DUCHAMP, Drifa BELHADI, Alpha DIALLO, Christelle DELMAS, Juliette SAILLARD, Aline DECHANET, Noémie MERCIER, Axelle DUPONT, Toni ALFAIATE, François-Xavier LESCURE, François RAFFI, François GOEHRINGER, Antoine KIMMOUN, Stéphane JAUREGUIBERRY, Jean REIGNIER, Saad NSEIR, François DANION, Raphael CLERE-JEHL, Kévin BOUILLER, Jean-Christophe NAVELLOU, Violaine TOLSMA, André CABIE, Clément DUBOST, Johan COURJON, Sylvie LEROY, Joy MOOTIEN, Rostane GACI, Bruno MOURVILLIER, Emmanuel FAURE, Valérie POURCHER, Sébastien GALLIEN, Odile LAUNAY, Karine LACOMBE, Jean-Philippe LANOIX, Alain MAKINSON, Guillaume MARTIN-BLONDEL, Lila BOUADMA, Elisabeth BOTELHO-NEVERS, Amandine GAGNEUX-BRUNON, Olivier EPAULARD, Lionel PIROTH, Florent WALLET, Jean-Christophe RICHARD, Jean REUTER, Thérèse STAUB, Maya HITES, Marion NORET, Claire ANDREJAK, Gilles PEYTAVIN, Bruno LINA, Dominique COSTAGLIOLA, Yazdan YAZDANPANAH, Charles BURDET and France MENTRE

medRxiv 20218149 [Preprint], London, Cold Spring Harbor Laboratory Press, 2021, 1756-1833

English

Článek v odborném periodiku

30230 Other clinical medicine subjects

United Kingdom of Great Britain and Northern Ireland

není předmětem státního či obchodního tajemství

DisCoVeRy trial

RIV/00216224:14110/21:00124332

Faculty of Medicine

COVID-19; SARS-CoV-2; hydroxychloroquine; interferon beta-1a; lopinavir/ritonavir; randomized controlled trial

COVID-19; SARS-CoV-2; hydroxychloroquine; interferon beta-1a; lopinavir/ritonavir; randomized controlled trial

Excelence Science, INT, MU, RIV, user

International impact